GLP-1 Receptor Agonists in Solid Tumour Therapy: Exploring Their Anticancer Potential and Underlying Molecular Pathways
Genes · 10.11.2025 · 16 (11) · 1352
DOI: 10.3390/genes16111352 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Genes, online erschienen am 10.11.2025. Verfasst von Daniela Lucente und 2 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, 00161 Rome, Italy. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially developed to treat type 2 diabetes mellitus, are now being investigated as agents in oncology. Recent preclinical studies have demonstrated their antitumor activity in several solid malignancies, including pancreatic, colorectal, breast, and prostate. Importantly, GLP-1 RAs modulate key signalling pathways such as PI3K/Akt, PKA, and AMPK, and exert anti-inflammatory effects by reducing cytokine production and macrophage infiltration. Preclinical data support their antineoplastic activity in vitro and in vivo, particularly by inhibiting tumour growth and metastasis. Nevertheless, there are ongoing concerns about tumorigenic effects in certain cancer types. This review critically examines the molecular mechanisms by which GLP-1 RAs influence cancer cell proliferation, apoptosis, angiogenesis, and inflammation, and emphasizes the need for further clinical studies to determine their therapeutic relevance. It also proposes assessing GLP-1 RAs as adjuncts in the management of solid tumours.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, 00161 Rome, Italy.
ORCID-Profile: Stefania Bellino, Anna La Salvia
Zitieren
APA
Lucente, D., Bellino, S., & La Salvia, A. (2025). GLP-1 Receptor Agonists in Solid Tumour Therapy: Exploring Their Anticancer Potential and Underlying Molecular Pathways. Genes, 16(11), 1352. https://doi.org/10.3390/genes16111352
Vancouver
Lucente D, Bellino S, La Salvia A. GLP-1 Receptor Agonists in Solid Tumour Therapy: Exploring Their Anticancer Potential and Underlying Molecular Pathways. Genes. 2025;16(11):1352. doi:10.3390/genes16111352
BibTeX
@article{Lucente2025,
author = {Lucente, Daniela and Bellino, Stefania and La Salvia, Anna},
title = {GLP-1 Receptor Agonists in Solid Tumour Therapy: Exploring Their Anticancer Potential and Underlying Molecular Pathways},
journal = {Genes},
year = {2025},
volume = {16},
number = {11},
pages = {1352},
doi = {10.3390/genes16111352}
}
EUVIMED